To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biogen is set to receive as much as $250 million in funding to develop a late-stage experimental lupus ...
Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Biogen (NASDAQ:BIIB) in the last three months. The following table summarizes their recent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback